|
1
|
Ghouri YA, Mian I and Rowe JH: Review of
hepatocellular carcinoma: Epidemiology, etiology, and
carcinogenesis. J Carcinog. 16:12017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burkhart RA, Ronnekleiv-Kelly SM and
Pawlik TM: Personalized therapy in hepatocellular carcinoma:
Molecular markers of prognosis and therapeutic response. Surg
Oncol. 26:138–145. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mazzoccoli G, Miele L, Oben J, Grieco A
and Vinciguerra M: Biology, epidemiology, clinical aspects of
hepatocellular carcinoma and the role of sorafenib. Curr Drug
Targets. 17:783–799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cai WF, Wang L, Liu GS, Zhu P, Paul C and
Wang Y: Manipulating the Hippo-Yap signal cascade in stem cells for
heart regeneration. Ann Palliat Med. 5:125–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xiao Y, Leach J, Wang J and Martin JF:
Hippo/Yap signaling in cardiac development and regeneration. Curr
Treat Options Cardiovasc Med. 18:382016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou Z, Zhu JS and Xu ZP: RNA interference
mediated YAP gene silencing inhibits invasion and metastasis of
human gastric cancer cell line SGC-7901. Hepatogastroenterology.
58:2156–2161. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Wang G, Chu SJ, Zhu JS, Zhang R,
Lu WW, Xia LQ, Lu YM, Da W and Sun Q: Loss of large tumor
suppressor 1 promotes growth and metastasis of gastric cancer cells
through upregulation of the YAP signaling. Oncotarget.
7:16180–16193. 2016.PubMed/NCBI
|
|
9
|
Ahmed AA, Mohamed AD, Gener M, Li W and
Taboada E: YAP and the Hippo pathway in pediatric cancer. Mol Cell
Oncol. 4:e12951272017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Shen H, Withers HG, Yang N,
Denson KE2, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C
and Zhang J: VGLL4 selectively represses YAP-dependent gene
induction and tumorigenic phenotypes in breast cancer. Sci Rep.
7:61902017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang
A, Wen W and Zhu Q: Overexpression of YAP and TAZ is an independent
predictor of prognosis in colorectal cancer and related to the
proliferation and metastasis of colon cancer cells. PLoS One.
8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Wang G, Yang Y, Mei Z, Liang Z, Cui
A, Wu T, Liu CY and Cui L: Increased TEAD4 expression and nuclear
localization in colorectal cancer promote epithelial-mesenchymal
transition and metastasis in a YAP-independent manner. Oncogene.
35:2789–2800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C, Zhu ZM, Liu CL, He XJ, Zhang HY
and Dong JH: Knockdown of yes-associated protein inhibits
proliferation and downregulates large tumor suppressor 1 expression
in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep.
11:4101–4108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tian Y, Tang B, Wang C, Sun D, Zhang R,
Luo N, Han Z, Liang R, Gao Z and Wang L: Metformin mediates
resensitivity to 5-fluorouracil in hepatocellular carcinoma via the
suppression of YAP. Oncotarget. 7:46230–46241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu S, Miao R, Zhai M, Pang Q, Deng Y, Liu
S, Qu K, Liu C and Zhang J: Effects and related mechanisms of
serotonin on malignant biological behavior of hepatocellular
carcinoma via regulation of Yap. Oncotarget. 8:47412–47424.
2017.PubMed/NCBI
|
|
16
|
Hermanek P and Sobin LH: (International
Union Against Cancer), TNM Classification of Malignant Tumors. 4th
edition. 2nd rev.Berlin: Germany Springer; 1992
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsieh YH, Hsieh SC, Lee CH, Yang SF, Cheng
CW, Tang MJ, Lin CL, Lin CL and Chou RH: Targeting EMP3 suppresses
proliferation and invasion of hepatocellular carcinoma cells
through inactivation of PI3K/Akt pathway. Oncotarget.
6:34859–34874. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu L, Zheng J, Chen P, Liu Q and Yuan Y:
Small nucleolar RNA ACA11 promotes proliferation, migration and
invasion in hepatocellular carcinoma by targeting the PI3K/AKT
signaling pathway. Biomed Pharmacother. 90:705–712. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Yuan J, Zhang X, Yan F, Huang M,
Wang T, Zheng X and Zhang M: Angiomotin promotes the malignant
potential of colon cancer cells by activating the YAP-ERK/PI3K-AKT
signaling pathway. Oncol Rep. 36:3619–3626. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang C, Gu C, Jeong KJ, Zhang D, Guo W, Lu
Y, Ju Z, Panupinthu N, Yang JY, Gagea MM, et al: YAP/TAZ-mediated
upregulation of GAB2 leads to increased sensitivity to growth
factor-induced activation of the PI3K pathway. Cancer Res.
77:1637–1648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Khanal P, Savage P, She YM, Cyr TD
and Yang X: YAP-induced resistance of cancer cells to antitubulin
drugs is modulated by a Hippo-independent pathway. Cancer Res.
74:4493–4503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Keren-Paz A, Emmanuel R and Samuels Y: YAP
and the drug resistance highway. Nat Genet. 47:193–194. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu PC, You B, Yang YL, Zhang WQ, Wang YC,
Xu Z, Dai Y, Liu S, Yang CT, Li H, et al: YAP promotes erlotinib
resistance in human non-small cell lung cancer cells. Oncotarget.
7:51922–51933. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Wang S, Wang G, Zhang Z, Wu X, Zhang
T, Fu B and Chen G: Yes-associated protein expression is a
predictive marker for recurrence of hepatocellular carcinoma after
liver transplantation. Dig Surg. 31:468–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fitamant J, Kottakis F, Benhamouche S,
Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M,
Deshpande V, et al: YAP inhibition restores hepatocyte
differentiation in advanced HCC, leading to tumor regression. Cell
Rep. Mar 10–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang S, Li H, Wang G, Zhang T, Fu B, Ma M,
Quan Z and Chen G: Yes-associated protein (YAP) expression is
involved in epithelial-mesenchymal transition in hepatocellular
carcinoma. Clin Transl Oncol. 18:172–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dong Q, Fu L, Zhao Y, Du Y, Li Q, Qiu X
and Wang E: Rab11a promotes proliferation and invasion through
regulation of YAP in non-small cell lung cancer. Oncotarget.
8:27800–27811. 2017.PubMed/NCBI
|
|
29
|
Lee JE, Park HS, Lee D, Yoo G, Kim T, Jeon
H, Yeo MK, Lee CS, Moon JY, Jung SS, et al: Hippo pathway effector
YAP inhibition restores the sensitivity of EGFR-TKI in lung
adenocarcinoma having primary or acquired EGFR-TKI resistance.
Biochem Biophys Res Commun. 474:154–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu X, Feng J, Zeng D, Ding Y, Yu C and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEK/ERK-dependent pathways. Biosci Rep. 34:pii:
e00094. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiong Z, Fu Z, Shi J, Jiang X and Wan H:
HtrA1 down-regulation induces cisplatin resistance in colon cancer
by increasing XIAP and activating PI3K/Akt pathway. Ann Clin Lab
Sci. 47:264–270. 2017.PubMed/NCBI
|
|
32
|
Huo X, Zhang Q, Liu AM, Tang C, Gong Y,
Bian J, Luk JM, Xu Z and Chen J: Overexpression of Yes-associated
protein confers doxorubicin resistance in hepatocellullar
carcinoma. Oncol Rep. 29:840–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
